Side Effects of talazoparib: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of talazoparib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of talazoparib: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of talazoparib: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Talazoparib is a PARP inhibitor that has been shown to be effective in treating metastatic breast cancer in patients with BRCA gene mutations, as shown in 11 . However, 2 reports that while talazoparib monotherapy showed some efficacy in Chinese patients with advanced solid tumors, side effects are a concern. Additionally, 12 indicates that patients with DNA repair gene mutations experience more pronounced side effects from combination therapy with talazoparib and carboplatin.

Reasons for Side Effects

Talazoparib works by inhibiting the DNA repair pathway, slowing cancer cell growth. However, it also inhibits DNA repair in normal cells, leading to side effects. Additionally, talazoparib is metabolized in the liver and excreted from the body. Side effects can occur during this metabolic process.

Common Side Effects

Blood Abnormalities

2 reported that in 15 Chinese patients who received talazoparib monotherapy, 20.0% experienced grade 3 side effects, 13.3% experienced grade 4 side effects, and 13.3% experienced serious side effects in blood tests. Additionally, 12 reported that patients with DNA repair gene mutations showed more pronounced blood test abnormalities (neutropenia, thrombocytopenia) with combination therapy of talazoparib and carboplatin.

Fatigue

12 reported that 13% of patients experienced grade 3 fatigue with combination therapy of talazoparib and carboplatin.

Nausea, Vomiting

Talazoparib may cause side effects such as nausea and vomiting. This is thought to be due to the drug's effect on the digestive system.

Loss of Appetite

Talazoparib may cause side effects such as loss of appetite. This is thought to be due to the drug's effect on the digestive system.

Gastrointestinal Problems

Talazoparib may cause gastrointestinal problems. This is thought to be due to the drug's effect on the digestive system.

Countermeasures for Side Effects

Blood Abnormalities

If blood abnormalities occur, measures such as blood transfusions or the administration of hematopoietic factors may be necessary.

Fatigue

To reduce fatigue, it is important to get enough rest and engage in physical activities that help build strength. It may also be necessary to consider drug therapy to reduce fatigue under the guidance of a doctor.

Nausea, Vomiting

If nausea and vomiting occur, drug therapy with antiemetics and anti-vomiting medications is employed. Dietary modifications may also be effective.

Loss of Appetite

If loss of appetite occurs, dietary modifications and nutritional supplements may be necessary. It may also be necessary to consider drug therapy to stimulate appetite under the guidance of a doctor.

Gastrointestinal Problems

If gastrointestinal problems occur, measures such as dietary modifications and drug therapy will be required.

Comparison Across Studies

Commonalities Among Studies

Many studies have shown that talazoparib is effective in treating metastatic breast cancer in patients with BRCA gene mutations. They also share the finding that talazoparib may cause side effects such as blood abnormalities and fatigue.

Differences Among Studies

The incidence and severity of side effects vary across studies. This is likely due to differences in the patient populations and treatment methods studied. For example, 12 reports that combination therapy of talazoparib and carboplatin results in more pronounced blood test abnormalities in patients with DNA repair gene mutations.

Considerations for Real-World Application

Talazoparib is an effective cancer treatment drug, but it can have strong side effects, particularly blood abnormalities and fatigue. It is important to consult with a doctor when considering talazoparib and make an informed decision after understanding the risks and benefits.

Current Research Limitations

Research on the side effects of talazoparib is still not comprehensive. Further research is needed, particularly on long-term side effects and side effects in specific patient populations.

Future Research Directions

To better understand the side effects of talazoparib, the following research is necessary:

  • Research on long-term side effects
  • Research on side effects in specific patient populations
  • Development of new therapies to reduce side effects

Conclusion

Talazoparib is an effective treatment for metastatic breast cancer in patients with BRCA gene mutations, but it is important to be aware of its strong side effects, particularly blood abnormalities and fatigue. When considering talazoparib, it is essential to consult with a doctor and make an informed decision after carefully weighing the risks and benefits.

Literature analysis of 12 papers
Positive Content
12
Neutral Content
0
Negative Content
0
Article Type
1
0
0
3
12
1.

The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.

Author: PopLucian, SuciuIoan, IonescuOlivia, BacalbasaNicolae, IonescuParis

Breast cancer treatment
Gastrointestinal side effects
Hematological side effects

PARP inhibitors are drugs that help kill cancer cells. They are used to treat breast cancers that have a BRCA1 or BRCA2 gene mutation. They have been shown to be effective, but they can cause side effects, such as problems with blood cells and the digestive system.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors.

Author: LuoYang, ChengYing, WuChunjiao, YeHui, ChenNaihan, ZhangFan, WeiHua, XuBinghe

Breast cancer treatment
Prostate cancer treatment
Adverse effects

This study investigated the pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. The study found that the pharmacokinetic profile of talazoparib monotherapy was consistent with other patient populations and that TEAEs were generally manageable with no unexpected safety findings.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.

Author: BaldwinPaige, OhmanAnders W, MedinaJamie E, McCarthyEric T, DinulescuDaniela M, SridharSrinivas

Ovarian cancer treatment
Side effects

Talazoparib is a potent PARP inhibitor for ovarian cancer treatment. This study developed a nanoparticle delivery system (NanoTalazoparib) to target peritoneal dissemination and improve efficacy while minimizing side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

[Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer].

Author: GrimmMarc-Oliver, FollerSusan, LeuchtKatharina

mCRPC treatment
Side effects

PARPi plus ARPi combination therapies have been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients with BRCA mutations. The article discusses the pivotal clinical trials, potential side effects, and management strategies for these combination therapies.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : German

5.

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.

Author: AgarwalAmit, BaghmarSaphalta, DodagoudarChandragouda, QureshiSuhail, KhuranaAseem, VaibhavVikas, KumarGuresh

Effective for BRCA-mutated ovarian cancer
Limited data for platinum-resistant ovarian cancer

This retrospective study evaluated the efficacy of poly(ADP-ribose) polymerase inhibitors (PARPi) in patients with platinum-resistant ovarian cancer (PROC). While PARPi have proven efficacy in platinum-sensitive ovarian cancers, more data is needed to assess their role in PROC.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

Author: de BonoJohann S, MehraNiven, ScagliottiGiorgio V, CastroElena, DorffTanya, StirlingAdam, StenzlArnulf, FlemingMark T, HiganoCelestia S, SaadFred, ButtiglieroConsuelo, van OortInge M, LairdA Douglas, MataMarielena, ChenHsiang-Chun, HealyCynthia G, CzibereAkos, FizaziKarim

Metastatic castration-resistant prostate cancer treatment

This study evaluated the effectiveness of the PARP inhibitor talazoparib in treating metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations. The research focused on the role of PARP inhibitors in targeting cancers with specific genetic vulnerabilities, offering a potential therapeutic strategy for these patients.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Targeted therapy for breast cancer in older patients.

Author: PondéNoam, WildiersHans, AwadaAhmad, de AzambujaEvandro, DeliensCoralie, LagoLissandra Dal

Breast cancer treatment
Targeted agent side effects

This review examines the efficacy and safety of targeted agents used in breast cancer treatment for older patients, a population often underrepresented in clinical trials. It provides an older-specific context for side effects and aims to help medical oncologists make informed treatment decisions for this patient group.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

12.

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.

Author: DhawanMallika S, BartelinkImke H, AggarwalRahul Raj, LengJim, ZhangJenna Z, PawlowskaNela, Terranova-BarberioManuela, GrabowskyJennifer A, GewitzAndrew, ChienAmy J, MoasserMark, KelleyRobin K, MaktabiTayeba, ThomasScott, MunsterPamela N

Cancer treatment
Tumor regression
Fatigue
Hematotoxicity

The PARP inhibitor talazoparib showed efficacy when combined with carboplatin in patients with germline BRCA1/2 mutations. However, this combination therapy also had significant hematologic toxicity. Pharmacokinetic modeling suggests that intermittent dosing of talazoparib, differentiated by germline and somatic DNA damage mutation status, may improve the benefit-risk ratio of this treatment.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.